US FDA Considering Contracting IT Services To Keep Systems Up To Date, Break Down Siloes
Executive Summary
Common system throughout FDA also could facilitate cross-center product reviews; Sentinel program is template for the approach.
You may also be interested in...
Advocates Press For US FDA Rare Disease Center Of Excellence
Attorneys' proposal aims to better connect dispersed rare disease expertise within FDA's drug, biologic, and device centers through more leadership, new advisory committee.
New CDER No. 2 May Impact FDA's Safety Monitoring Aspirations
Patrizia Cavazzoni, CDER's new deputy director for operations, has safety surveillance background and wants to see FDA continue to grow its capabilities.
US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say
CDER's OHOP, as well as relevant CBER and CDRH staff, should be folded into OCE, which should have final sign-off on all oncology products, ASCO and Friends of Cancer Research say.